Gingival Enlargement (Carranza's Clinical Periodontology) - Detailed LAQ

Definition

Terminology

• Hypertrophy: Increase in size of individual cells
• Hyperplasia: Increase in the number of cells
• Fibrosis: Accumulation of collagenous connective tissue (acellular)
• Edema: Presence of excess fluid in intercellular spaces

Classification (Carranza)

I. Based on Etiologic Factors and Pathologic Changes

1. Chronic inflammatory enlargement
2. Acute inflammatory enlargement (abscess)

1. Anticonvulsants - Phenytoin (Dilantin)
2. Calcium channel blockers - Nifedipine, amlodipine, diltiazem, verapamil
3. Immunosuppressants - Cyclosporine A

1. Conditioned enlargements
   • Pregnancy-associated
   • Puberty-associated
   • Vitamin C deficiency (scurvy)
   • Plasma cell gingivitis
   • Nonspecific conditioned enlargements (pyogenic granuloma)
2. Systemic disease enlargements
   • Leukemia-associated
   • Granulomatous diseases (Wegener's granulomatosis, sarcoidosis, Crohn's disease)

1. Benign - Fibroma, papilloma, peripheral giant cell granuloma, hemangioma
2. Malignant - Squamous cell carcinoma, malignant melanoma

• Due to increase in size of underlying bone or teeth (e.g., tori, exostosis, Paget's disease, during tooth eruption)

II. Based on Location and Distribution

III. Scoring of Gingival Enlargement (Gavaldá et al.)

1. Inflammatory Enlargement

A. Chronic Inflammatory Enlargement

• Begins as slight ballooning of interdental papillae and marginal gingiva
• A "life-preserver shaped" bulge appears around involved teeth
• Can enlarge to cover crowns of teeth
• Usually painless unless trauma or acute infection is superimposed
• Bluish-red or deep red in color
• Soft, edematous consistency; bleeds on probing
• As the condition becomes more chronic - firm, fibrotic, pink, stippled surface
• False pockets (pseudopockets) formed due to the coronal position of the gingival margin

• Chronic inflammatory cells: lymphocytes, plasma cells, macrophages
• Edema, vascular proliferation (angiogenesis)
• Fibroblast proliferation and collagen deposition in chronic stages
• Epithelial proliferation with rete peg extension

• Scaling and root planing (Phase I therapy)
• Improved oral hygiene
• Gingivectomy if gingiva remains enlarged after Phase I

B. Acute Inflammatory Enlargement (Periodontal Abscess)

1. Gingival abscess - Localized, involves only gingival tissue; caused by foreign body impaction
2. Periodontal abscess - Associated with a periodontal pocket
3. Pericoronal abscess - Around a partially erupted tooth

• Rapid onset, localized, painful swelling
• Fluctuant, red, shiny surface
• Purulent exudate on probing
• Associated tooth may be tender to percussion

• Drainage (incision or via pocket)
• Antibiotics (systemic) if systemic signs present
• Definitive periodontal therapy after acute phase resolves

2. Drug-Induced (Drug-Influenced) Gingival Enlargement (DIGE)

Causative Drugs

• Phenytoin was the first drug reported (Kimball, 1939)
• Cyclosporine + nifedipine together produce synergistic enlargement

Pathogenesis

• Not all patients on these drugs develop enlargement
• Certain individuals have a genetically susceptible subpopulation of fibroblasts that overrespond to the drug
• These fibroblasts show elevated protein synthesis and collagen production
• The ratio of "responsive" to "non-responsive" fibroblast subsets determines susceptibility

• Drugs (especially phenytoin) reduce collagen degradation by inhibiting collagenase activity
• Simultaneously enhance collagen synthesis by fibroblasts
• Net result: excessive accumulation of collagen in connective tissue

• Dental plaque induces IL-1β and IL-6 in gingival tissues
• IL-1β synergistically enhances collagenous protein synthesis by fibroblasts when combined with nifedipine
• IL-6 stimulates fibroblast proliferation and upregulates collagen and glycosaminoglycan synthesis
• Cyclosporine-induced gingival lesions show dramatically elevated IL-6 expression
• This explains why good plaque control reduces severity

• Phenytoin may interfere with folic acid uptake by gingival cells
• Reduced folic acid activity may impair normal cell regulation

• Altered keratinocyte growth factor (KGF) production by fibroblasts may stimulate epithelial proliferation

Clinical Features of Each Drug

• Begins as painless beadlike enlargement of interdental papillae
• Granular or pebbly surface with enlargement of interdental papilla
• Pseudoclefts form between enlarged papillae
• Growth diminishes at the mucogingival junction but continues coronally
• May partially or completely obscure the teeth
• Firm, pale pink, stippled (fibrotic) consistency
• Does NOT occur in edentulous areas (requires teeth/alveolar bone)
• More common and severe in children and adolescents
• Prevalence: ~50%; males > females (3:1)
• Phenytoin accelerates gingival wound healing

• More prominent on the labial surface
• Hyperemic, soft, friable tissue
• High bleeding tendency
• More vascular and edematous compared to phenytoin-induced
• Associated with increased susceptibility to infections
• Prevalence: ~25-30%

• Initially affects the papillary region
• Lobular and nodular morphology
• Extends to attached gingiva
• Firm, pale pink, less inflamed than cyclosporine type
• Nifedipine has the highest prevalence (up to 86%)
• Amlodipine, diltiazem, verapamil also implicated but lower prevalence

Risk Factors for DIGE

• Poor oral hygiene / dental plaque (most important modifiable risk factor)
• Young age (children and teenagers more susceptible to phenytoin and cyclosporine)
• Male sex (3x more likely)
• Genetic susceptibility (fibroblast subpopulations, HLA class II antigens)
• Drug dosage (controversial - dose-dependent association debated)
• Combination of inducing drugs (synergistic effect)

Histopathology of DIGE

• Stratified squamous epithelium with elongated rete pegs projecting into connective tissue
• Connective tissue shows dense collagen bundles with relative acellularity (fibrosis)
• Scattered chronic inflammatory cells
• Increased fibroblasts and fibroblast activity
• Increased ground substance (glycosaminoglycans)
• In cyclosporine-induced: more vascular component, more inflammatory cells

Treatment of DIGE

• Thorough scaling and root planing
• Plaque control and oral hygiene instruction
• Antiseptic mouthrinse (chlorhexidine 0.12%)
• Re-evaluate after 6-8 weeks - significant reduction may occur with this alone in mild cases

• Consult with the prescribing physician
• Phenytoin → carbamazepine or valproic acid (induce less enlargement)
• Nifedipine → beta-blockers, ACE inhibitors, diltiazem, or verapamil
• Cyclosporine A → tacrolimus (FK-506, significantly less gingival enlargement)
• Note: physicians and patients may be reluctant to change well-controlled regimens

• Indicated when enlargement persists after Phase I therapy and drug substitution
• Gingivectomy: conventional method; simple excision of excess gingiva using periodontal knives (Kirkland, Orban), electrosurgery, or laser
• Periodontal flap surgery (Modified Widman flap / Undisplaced flap): preferred when osseous involvement exists, when access is needed, or when keratinized tissue must be preserved
• Laser gingivectomy (diode, CO2, Nd:YAG): excellent hemostasis, especially useful in cyclosporine-induced (highly vascular tissue)

• Enlargement recurs if the drug is not changed
• Recurrence rate is high (up to 100% for phenytoin if drug continued)
• Recurrence can be minimized by excellent plaque control after surgery
• Re-treatment is often necessary every 1-2 years

3. Enlargements Associated with Systemic Diseases

A. Conditioned Enlargements

• Called "pregnancy tumor" (pyogenic granuloma / pregnancy epulis) when discrete
• Generalized form also seen
• Due to altered hormonal milieu (increased progesterone and estrogen)
• Heightened inflammatory response to dental plaque
• Appears from 2nd month of pregnancy; peaks in 8th month
• Pyogenic granuloma: red, soft, hemorrhagic, pedunculated or sessile; usually on labial aspect of interdental papilla
• Histology: endothelial proliferation, vascular channels, mixed inflammatory infiltrate
• Often regresses after delivery
• Treatment: scaling and plaque control; excision if large or interfering with function; best done after delivery unless urgent

• Occurs in both sexes during puberty
• Increased sex hormones alter vascular response and inflammatory mediators
• Clinical features similar to chronic inflammatory enlargement but more pronounced
• Often regresses after puberty if oral hygiene improved

• Ascorbic acid needed for collagen synthesis and fibroblast function
• Deficiency → impaired collagen synthesis → increased vascular permeability
• Gingiva: bright red/bluish-red, soft, hemorrhagic, necrotic margins
• "Scorbutic gingiva"
• Often confused with other forms of inflammatory enlargement
• Treatment: Vitamin C supplementation + plaque control

• Reactive hyperplasia to local irritation
• Pedunculated or sessile, hemorrhagic, red/purple
• Located on buccal/labial interdental papilla
• Histology: profuse endothelial proliferation, thin-walled blood vessels, inflammatory cells
• Treatment: surgical excision with elimination of local irritating factors

B. Systemic Disease Enlargements

• Most common with acute monocytic and myelomonocytic leukemia (AML M4/M5)
• Due to massive infiltration of leukemic cells in gingival connective tissue
• Clinically: bluish-red, spongy, smooth surface; bleeds spontaneously
• Associated features: oral ulceration, spontaneous gingival bleeding, petechiae, mucosal pallor, candidiasis
• May be the presenting sign of undiagnosed leukemia
• Investigation: complete blood count (CBC)
• Treatment: management of underlying leukemia; local plaque control (may not regress fully without systemic treatment)

• Wegener's granulomatosis: "strawberry gingivitis" - red, granular, hemorrhagic gingival enlargement
• Sarcoidosis: noncaseating granulomas in gingival tissue
• Crohn's disease: cobblestone-like gingival enlargement with mucosal tags

4. Neoplastic Enlargements

Benign Tumors

Malignant Tumors

• Squamous cell carcinoma: Most common oral cancer; may present as ulcerative or exophytic gingival mass; often painless early
• Malignant melanoma: Pigmented, rapidly growing; rare but poor prognosis

5. False Enlargement

• Not a true enlargement of gingival tissue
• Gingiva is normal but appears enlarged due to increase in underlying structures
• Causes:
  • Underlying bone: tori, exostosis, Paget's disease, cherubism, osteoma, fibrous dysplasia
  • Dental tissue: tooth eruption (eruption cyst/bulge)
• Gingiva presents with normal clinical features; no inflammation
• Diagnosis confirmed by radiograph showing underlying bone expansion
• Treatment: management of underlying cause

Differential Diagnosis Summary

Summary of Treatment Principles

1. Phase I therapy is mandatory before any surgical intervention
2. Eliminate local factors (scaling, root planing, oral hygiene instruction)
3. Address systemic cause (drug substitution, hormone normalization, systemic disease management)
4. Surgical excision (gingivectomy or flap) for persistent enlargement after Phase I
5. Maintenance care to prevent recurrence
6. Biopsy for any lesion with uncertain etiology or malignant features